CMND Relative Valuation
CMND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CMND is overvalued; if below, it's undervalued.
Historical Valuation
Clearmind Medicine Inc (CMND) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Clearmind Medicine Inc (CMND) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price:2.43
Fair
0.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Clearmind Medicine Inc. (CMND) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Clearmind Medicine Inc. (CMND) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Clearmind Medicine Inc. (CMND) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Clearmind Medicine Inc. (CMND) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Clearmind Medicine Inc. (CMND) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Clearmind Medicine Inc (CMND) has a current Price-to-Book (P/B) ratio of 0.25. Compared to its 3-year average P/B ratio of 1.56 , the current P/B ratio is approximately -83.86% higher. Relative to its 5-year average P/B ratio of 2.59, the current P/B ratio is about -90.32% higher. Clearmind Medicine Inc (CMND) has a Forward Free Cash Flow (FCF) yield of approximately -151.64%. Compared to its 3-year average FCF yield of -134.17%, the current FCF yield is approximately 13.02% lower. Relative to its 5-year average FCF yield of -115.23% , the current FCF yield is about 31.60% lower.
0.25
P/B
Median3y
1.56
Median5y
2.59
-151.64
FCF Yield
Median3y
-134.17
Median5y
-115.23
Competitors Valuation Multiple
The average P/S ratio for CMND's competitors is 2.23, providing a benchmark for relative valuation. Clearmind Medicine Inc Corp (CMND) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CMND increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CMND in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Clearmind Medicine Inc (CMND) currently overvalued or undervalued?
Clearmind Medicine Inc (CMND) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Clearmind Medicine Inc (CMND) is between to according to relative valuation methord.
What is Clearmind Medicine Inc (CMND) fair value?
CMND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Clearmind Medicine Inc (CMND) is between to according to relative valuation methord.
How does CMND's valuation metrics compare to the industry average?
The average P/S ratio for CMND's competitors is 2.23, providing a benchmark for relative valuation. Clearmind Medicine Inc Corp (CMND) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Clearmind Medicine Inc (CMND) as of Jan 08 2026?
As of Jan 08 2026, Clearmind Medicine Inc (CMND) has a P/B ratio of 0.25. This indicates that the market values CMND at 0.25 times its book value.
What is the current FCF Yield for Clearmind Medicine Inc (CMND) as of Jan 08 2026?
As of Jan 08 2026, Clearmind Medicine Inc (CMND) has a FCF Yield of -151.64%. This means that for every dollar of Clearmind Medicine Inc’s market capitalization, the company generates -151.64 cents in free cash flow.
What is the current Forward P/E ratio for Clearmind Medicine Inc (CMND) as of Jan 08 2026?
As of Jan 08 2026, Clearmind Medicine Inc (CMND) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Clearmind Medicine Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Clearmind Medicine Inc (CMND) as of Jan 08 2026?
As of Jan 08 2026, Clearmind Medicine Inc (CMND) has a Forward P/S ratio of 0.00. This means the market is valuing CMND at $0.00 for every dollar of expected revenue over the next 12 months.